

Heterozygous p.I171V mutation of the *NBN* gene as a risk factor for lung cancer development

EWELINA MARIA KAŁUŻNA¹, JOLANTA REMBOWSKA¹, IWONA ZIÓŁKOWSKA-SUCHANEK¹,
BOGNA ŚWIĄTEK-KOŚCIELNA¹, PIOTR GABRYEL²,
WOJCIECH DYSZKIEWICZ² and JERZY STANISŁAW NOWAK¹

¹Department of Molecular Pathology, Institute of Human Genetics of the Polish Academy of Sciences, Poznań 60-479;

²Department of Thoracic Surgery, University of Medical Sciences, Poznań 60-569, Poland

Received May 23, 2014; Accepted August 17, 2015

DOI: 10.3892/ol.2015.3715

Abstract. The *NBN* gene, also known as *NBS1*, is located on the chromosome band 8q21.3, and encodes a 754-amino acid-long protein named nibrin. This protein is a member of the MRE1-RAD50-NBN nuclear complex, and is involved in numerous cell processes essential for maintaining genomic stability. Heterozygous variants in the *NBN* gene, including p.I171V, c.657del5 and p.R215W, have been described as risk factors for the development of several malignancies. However, there is no report regarding the association of these mutations with lung cancer thus far. Therefore, the present study aimed to evaluate whether there is an association between the heterozygous p.I171V, c.657del5 and p.R215W variants of the *NBN* gene and the risk of developing lung cancer. The frequency of these variants was estimated in a group of 453 adults diagnosed with non-small cell lung cancer (NSCLC) and in healthy controls (2,400 for p.I171V, 2,090 for c.657del5 and 498 for p.R215W). The p.I171V variant was assessed by restriction fragment length polymorphism analysis of polymerase chain reaction (PCR) products, using *MunI* (*MfeI*) restriction enzyme, whereas the c.657del5 and p.R215W variants were assessed by the PCR single-strand conformation polymorphism method. A significantly increased risk of developing lung cancer was observed

for the p.I171V variant, which was present in 17 (3.75%) of the 453 cases of lung cancer and in 12 (0.5%) of the 2,400 healthy individuals (odds ratio, 7.759; $P < 0.0001$). The results obtained indicated an association between the p.I171V mutation and the development of lung cancer. Therefore, this variant may be considered a risk factor for NSCLC. Prospective studies with larger groups of patients may reveal the potential impact of the p.I171V variant in the occurrence of lung cancer.

Introduction

The *NBN* gene, also known as *NBS1*, is located on the chromosome band 8q21.3, and encodes a 754-amino acids-long protein termed nibrin (1). This protein is a member of the MRE1-RAD50-NBN (MRN) nuclear complex, and is involved in numerous cell processes that are essential for maintaining genomic stability, including the detection and repair of DNA double-strand breaks (DSBs), cell cycle checkpoint control, meiosis and induction of apoptosis (2-4). Therefore, any mutations disrupting its functionality may lead to genomic instability and promote tumorigenesis. Homozygous mutations in the *NBN* gene, resulting in the production of an abnormally short version of the nibrin protein, lead to Nijmegen breakage syndrome (NBS) and increased susceptibility to tumorigenesis (5-7). Heterozygous variants in this gene, including p.I171V (c.551A>G), c.657delACAAA and p.R215W (c.643C>T), have been described as risk factors for several malignancies, including leukemia, melanoma, breast, ovarian, prostate, larynx and colorectal cancer (8-12). To the best of our knowledge, there is no report regarding the association of the aforementioned mutations with lung cancer. Therefore, the present study aimed to evaluate whether there is an association between the heterozygous p.I171V, c.657del5 and p.R215W variants of the *NBN* gene and the risk of developing lung cancer.

Materials and methods

The frequency of constitutional mutations in the fifth and sixth exons of the *NBN* gene was estimated in a group of 453 adults (139 females and 314 males) diagnosed with lung cancer, and in healthy controls (2,400 for p.I171V,

Correspondence to: Ms. Ewelina Maria Kałużna, Department of Molecular Pathology, Institute of Human Genetics of the Polish Academy of Sciences, 32 Strzeszyńska Street, Poznań 60-479, Poland

E-mail: ewelina.kaluzna@o2.pl

Abbreviations: ALL, acute lymphoblastic leukemia; BRCT, BRCA1 carboxy-terminal; CI, confidence intervals; DSBs, DNA double-strand breaks; FHA, forkhead-associated domain; NBS, Nijmegen breakage syndrome; NSCLC, non-small cell lung cancer; OR, odds ratio; RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism

Key words: *NBN* gene, nibrin, p.I171V, lung cancer risk

Table I. Characteristics of the primers used for PCR.

Variant	Exon	Primer sequence	Product size (bp)	Tb (°C)
p.I171V c.511A>G	5	F: 5'-TTATGGATGTAAACAGCCTC-3' R: 5'-TACCGAACTATAACACAGCA-3'	328	54
c.657-661del c.657_651delACAAA	6	F: 5'-CAGATAGTCACTCGGTTTACAA-3' R: 5'-TTCTTTAGGAAAATTTAGCT-3'	228	50
p.R215W c.643C>T	6	F: 5'-CAGATAGTCACTCGGTTTACAA-3' R: 5'-ACAACACTGATAAGAGTTA-3'	273	50

PCR, polymerase chain reaction; F, forward; R, reverse; bp, base pairs; Tb, binding temperature.

Table II. Frequency of the *NBN* variants and results of the logistic regression analysis performed in patients diagnosed with lung cancer versus healthy controls.

Variant	Patients with lung cancer (%)	Healthy controls (%)	OR (95% CI)	P-value
p.I171V	17/453 (3.75)	12/2,400 (0.50)	7.759 (3.679-16.360)	<0.0001 ^a
c.657-661del	3/453 (0.66)	21/2,090 (1.00)	0.657 (0.195-2.212)	0.728
p.R215W	0/453 (0.00)	1/498 (0.20)	0.366 (0.015-9.006)	1.000

NBN, nibrin; OR, odds ratio; CI, confidence interval. ^aStatistically significant difference.

2,090 for c.657del5 and 498 for p.R215W). The cohort of 453 cases of lung cancer were recruited in the Department of Thoracic Surgery of the University of Medical Sciences in Poznań (Poznań, Poland). All the subjects enrolled in the study were of Caucasian ancestry from the Wielkopolska region of Poland. The majority of the cases were males (69%), with a median age of 63.5 years. The diagnosis of non-small cell lung cancer (NSCLC) was confirmed by histopathological examination. Anonymous blood samples, collected on Guthrie cards (Whatman 903[®]; Whatman Inc., Dassel, Germany) drawn from the newborn screening program of the Wielkopolska region, were used as controls. The results for the control samples were obtained in previous studies (10,13,14). All the patients signed an informed consent form approved by the Ethics Committee of the University of Medical Sciences in Poznań (approval no. 802/10).

DNA was extracted from blood using the columns provided in the QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions, and from Guthrie cards, as described previously (13,15). The mutation in the fifth exon of the *NBN* gene (p.I171V) was assessed by restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) products, using *MunI* (*MfeI*) restriction enzyme (Fermentas, Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). PCR reactions were performed in a total volume of 25 μ l containing 2.5 μ l of 10X PCR buffer with 15 mM MgCl₂ (Sigma-Aldrich, St. Louis, MO, USA), 6 pM of each primer, 2 mM of each deoxynucleotide triphosphate (dNTP; Sigma-Aldrich, Steinheim, Germany), 1.5 units of Taq DNA polymerase (Sigma-Aldrich, St. Louis, MO, USA) and 1.5 μ l of DNA template. Amplification conditions involved initial

denaturation for 5 min at 95°C, followed by 35 cycles of 25 sec at 95°C, 35 sec at 54°C and 55 sec at 72°C, with a 10-min final extension at 72°C. Next, 10 μ l of the PCR products were digested for 3 h at 37°C, and analyzed by electrophoresis on a 2% agarose gel, in the presence of ethidium bromide. The endonuclease *MunI* recognizes and cleaves the sequence CA*ATTG, which occurs only once in each of the analyzed fragments. The mutations in the sixth exon of the *NBN* gene (c.657del5 and p.R215W) were assessed by the PCR single-strand conformation polymorphism (SSCP) method. PCR reactions were performed in a total volume of 25 μ l containing 2.5 μ l of 10X PCR buffer with 15 mM MgCl₂, 6 pM of each primer, 2 mM of each dNTP, 1.5 units of Taq DNA polymerase and 1.5 μ l of DNA template. Amplification conditions involved initial denaturation for 3 min at 95°C, followed by 5 cycles of 25 sec at 95°C, 25 sec at 50°C and 55 sec at 72°C; then 30 cycles of 25 sec at 94°C, 35 sec at 48°C, 45 sec at 72°C, with a 6-min final extension at 72°C. Next, 4 μ l of the PCR products were mixed with 9 μ l of the loading buffer, and denatured for 5 min at 95°C, cooled and separated on 7% non-denaturing polyacrylamide gel for 40 h 4°C. Those samples exhibiting positive results were subsequently sequenced using the Sanger method. The conditions of PCR before sequencing were the same as those before RFLP analysis for p.I171V and SSCP analysis for c.657-661del and p.R214W. PCR products were cleaned up using NucleoSpin[®] Gel and PCR Clean-up kit (Macherey-Nagel, Inc., Düren, Germany) according to the manufacturer's protocol. The sequencing reaction protocol included 45 cycles of 10 sec at 94°C, 5 sec at 52°C and 3 min at 60°C. The sequences of all the primers used for PCR analysis in the present study are provided in Table I.




Figure 1. Allele frequency and results of logistic regression analysis corresponding to the p.I171V, c.657del5 and p.R215W variants of the *NBN* gene in the group of patients with lung cancer (N=453) vs. controls (p.I171V, N=2,400; c.657del5, N=2,090; p.R215W, N=498). P<0.05 was considered to indicate a statistically significant difference. OR, odds ratio; NBN, nibrin; *P<0.0001 vs control.

Statistical analysis. The allele frequencies among the groups were compared using the χ^2 and Fisher's exact tests, using GraphPad software version 5.03 (GraphPad Software Inc., La Jolla, CA, USA). The odds ratios (ORs) for the relative risk conferred by a particular variant were estimated with 95% confidence intervals (CI). P<0.05 was considered to indicate a statistically significant difference.

Results

The p.I171V variant in the fifth exon and the c.657del5 and p.R215W variants in the sixth exon of the *NBN* gene were analyzed in adult patients diagnosed with lung cancer (N=453) and in healthy controls (N=2,400 for p.I171V, N=2,090 for c.657del5 and N=498 for p.R215W).

The p.I171V (c.551A>G) variant was identified in 17 of the 453 cases of lung cancer and in 12 of the 2,400 healthy individuals (Table II and Fig. 1). These results indicate a significantly higher incidence of the p.I171V variant in patients with lung cancer, compared to healthy controls (OR=7.759, P<0.0001). Of the 17 patients with cancer exhibiting this variant, 2 were females (2/139) and 15 were males (15/314). The heterozygous c.657del5 mutation was identified in 3 of the 453 patients with lung cancer (OR=0.657, P=0.728) and in 5 of the 2,090 controls (Table II and Fig. 1). The p.R215W (c.634C>T) mutation was identified in 1 case from the control group, and was absent in the group of patients with lung cancer (Table II). The results of the RFLP, SSCP and sequencing analyses conducted on the relevant samples are presented in Fig. 2.

Discussion

Previous studies have reported an association between heterozygous variants in the *NBN* gene and susceptibility to certain malignancies (16), including acute lymphoblastic leukemia (ALL), melanoma, breast, ovarian, prostate, colorectal and

larynx cancer (8-12). The present study aimed to investigate whether variants in the *NBN* gene are associated with elevated risk of lung cancer incidence in adults.

The p.I171V variant in the fifth exon and the c.657del5 and p.R215W variants in the sixth exon of the *NBN* gene were analyzed in 453 adult patients diagnosed with lung cancer, and in healthy controls (2,400, 2,090 and 498 for p.I171V, c.657del5 and p.R215W, respectively).

A significantly increased risk of developing lung cancer was observed for the p.I171V (c.551A>G) variant, which was present in 17 of the 453 cases of lung cancer and in 12 of the 2,400 healthy individuals. These results indicate a higher incidence of the p.I171V variant in patients with lung cancer (OR=7.759, P<0.0001), and suggest that p.I171V may be a risk allele for lung cancer. Of the 17 patients with cancer who exhibited this variant, 2 were females (2/139) and 15 were males (15/314). The pathogenicity of the p.I171V variant is presumably associated with its location in the highly conserved breast cancer 1 (BRCA1) carboxy-terminal (BRCT) domain of the *NBN* gene. This BRCT domain, together with the forkhead-associated domain, participates in the translocation of the MRN complex to the sites of DSBs (17). Cersaletti and Concannon (18) demonstrated that mutations in these domains result in disorders in the formation of nuclear clusters and phosphorylation of nibrin following irradiation. The occurrence of the p.I171V variant in the *NBN* gene has been previously linked with elevated risk of several types of cancer. A significantly higher frequency of the p.I171V variant was observed in ALL, breast, larynx and colorectal cancer, and in multiple primary tumors of the head and neck (9,13,15). However, such an association was not observed for solid malignancies in children (11). By contrast, Ciara *et al* (19) reported an association between this variant and childhood medulloblastoma. Nonetheless, the *in vitro* studies conducted on cells derived from heterozygous carriers of the p.I171V variant have demonstrated that, *per se*, this variant does not play a crucial role in tumorigenesis (20).




Figure 2. (A) Sequencing results and RFLP analysis (using *MunI* restriction enzyme) corresponding to the p. I171V variant. Sequencing and SSCP analysis of the variants (B) c.657del5 and (C) p.R215W. The variants are indicated by an arrow. RFLP, restriction fragment length polymorphism; SSCP, single-strand conformation polymorphism; S, sample; p.R215W, reference sequence for heterozygous p.R215W substitution; c.657del5 het, reference sequence for heterozygous c.657del5 mutation; c.657del5 hom, reference sequence for homozygous c.657del5 mutation.

In the present study, the occurrence of the c.657del5 mutation in the sixth exon of the *NBN* gene was also analyzed. The heterozygous variant of this mutation was identified in 3 of 453 patients with lung cancer and in 5 of 2,090 controls. The occurrence of the c.657del5 variant, known as the Slavic mutation, results in the production of two truncated fragments of the nibrin protein (20). Thus, homozygous c.657del5 has a deleterious impact on nibrin function and leads to NBS, while the heterozygous variant has been associated with susceptibility to tumorigenesis (21). A higher frequency of occurrence

of the heterozygous c.657del5 mutation has been observed in patients with melanoma and non-Hodgkin lymphoma (22). However, other studies have reported that c.657del5 did not occur more frequently in breast (9,22), colorectal (22) and larynx cancer (13), which suggests that this variant is not a risk factor for these malignancies. Similarly, in the present study, no association between the occurrence of the c.657del5 mutation and the risk of developing lung cancer was observed.

The p.R215W (c.634C>T) mutation of the *NBN* gene was identified in 1 case from the control group, and it was absent

in the group of patients with lung cancer. This mutation was described for the first time in patients diagnosed with ALL (23). Previous studies conducted on a Caucasian population demonstrated that p.R215W carriers have an increased risk of non-Hodgkin lymphoma, colorectal, breast and prostate cancer (22,24,25). However, the results of the present study did not indicate that carriers of the p.R215W mutation have an elevated risk of developing lung cancer.

In summary, in the present study, a significantly higher frequency of the p.I171V variant in the fifth exon of the *NBN* gene was observed in patients diagnosed with NSCLC. The results obtained indicate an association between the occurrence of the p.I171V mutation and the development of lung cancer. Therefore, this variant may be considered as a risk factor for lung cancer. Prospective studies on a larger group of patients may reveal the potential impact of the p.I171V variant on the development of lung cancer.

Acknowledgements

The present study was partially supported by the National Science Centre grant no. 2011/01/D/NZ5/02841.

References

1. Weizmann Institute of Science: GeneCards: *NBN* gene. Weizmann Institute of Science, Rehovot, Israel, 2014.
2. Assenmacher N and Hopfner KP: MRE11/RAD50/NBS1: Complex activities. *Chromosoma* 113: 157-166, 2004.
3. D'Amours D and Jackson SP: The Mre11 complex: At the crossroads of dna repair and checkpoint signalling. *Nat Rev Mol Cell Biol* 3: 317-327, 2002.
4. Tauchi H, Matsuura S, Kobayashi J, Sakamoto S and Komatsu K: Nijmegen breakage syndrome gene, *NBS1*, and molecular links to factors for genome stability. *Oncogene* 21: 8967-8980, 2002.
5. Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR III, Hays L, Morgan WF and Petrini JH: The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response. *Cell* 93: 477-486, 1998.
6. Matsuura S, Tauchi H, Nakamura A, Kondo N, Sakamoto S, Endo S, Smeets D, Solder B, Belohradsky BH, Der Kaloustian VM, *et al*: Positional cloning of the gene for Nijmegen breakage syndrome. *Nat Genet* 19: 179-181, 1998.
7. Varon R, Vissinga C, Platzer M, Cersaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanová E, Cooper PR, Nowak NJ, *et al*: Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. *Cell* 93: 467-476, 1998.
8. Mosor M, Ziółkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D and Nowak J: Association of the heterozygous germline I171V mutation of the *NBS1* gene with childhood acute lymphoblastic leukemia. *Leukemia* 20: 1454-1456, 2006.
9. Roznowski K, Januszkiewicz-Lewandowska D, Mosor M, Pernak M, Litwiniuk M and Nowak J: I171V germline mutation in the *NBS1* gene significantly increases risk of breast cancer. *Breast Cancer Res Treat* 110: 343-348, 2008.
10. Ziółkowska I, Mosor M, Wierzbička M, Rydzanicz M, Pernak-Schwarz M and Nowak J: Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the *NBS1* gene. *Cancer Sci* 98: 1701-1705, 2007.
11. Nowak J, Mosor M, Nowicka K, Rembowska J and Januszkiewicz D: Is the *NBN* gene mutation I171V a potential risk factor for malignant solid tumors in children? *J Pediatr Hematol Oncol* 33: e248-e249, 2011.
12. Cybulski C, Górski B, Debiak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, *et al*: *NBS1* is a prostate cancer susceptibility gene. *Cancer Res* 64: 1215-1219, 2004.
13. Mosor M, Ziółkowska-Suchanek I, Nowicka K, Dzikiewicz-Krawczyk A, Januszkiewicz-Lewandowska D and Nowak J: Germline variants in MRE11/RAD50/*NBN* complex genes in childhood leukemia. *BMC Cancer* 13: 457-464, 2013.
14. Ziółkowska I, Mosor M and Nowak J: Regional distribution of heterozygous 657del5 mutation carriers of the *NBS1* gene in Wielkopolska province (Poland). *J Appl Genet* 47: 269-272, 2006.
15. Nowak J, Mosor M, Ziółkowska I, Wierzbička M, Pernak-Schwarz M, Przyborska M, Roznowski K, Pławski A, Słomski R and Januszkiewicz D: Heterozygous carriers of the I171V mutation of the *NBS1* gene have a significantly increased risk of solid malignant tumours. *Eur J Cancer* 44: 627-630, 2008.
16. Gao P, Ma N, Li M, Tian Q-B and Liu DW: Functional variants in *NBS1* and cancer risk: Evidence from a meta-analysis of 60 publications with 11 individual studies. *Mutagenesis* 28: 683-697, 2013.
17. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF and Koonin EV: A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. *FASEB J* 11: 68-76, 1997.
18. Cersaletti KM and Concannon P: Nibrin forkhead-associated domain and breast cancer C-terminal domain are both required for nuclear focus formation and phosphorylation. *J Biol Chem* 278: 21944-21951, 2003.
19. Ciara E, Piekutowska-Abramczuk D, Popowska E, Grajkowska W, Barszcz S, Perek D, Dembowska-Bagińska B, Perek-Polnik M, Kowalewska E, Czajńska A, *et al*: Heterozygous germ-line mutations in the *NBN* gene predispose to medulloblastoma in pediatric patients. *Acta Neuropathol* 119: 325-334, 2010.
20. Dzikiewicz-Krawczyk A, Mosor M, Januszkiewicz D and Nowak J: Impact of heterozygous c.657-661del, p.I171V and p.R215W mutations in *NBN* on nibrin functions. *Mutagenesis* 27: 337-343, 2012.
21. Seemanová E, Jarolim P, Seeman P, Varon R, Digweed M, Swift M and Sperling K: Cancer risk of heterozygotes with the *NBN* founder mutation. *J Natl Cancer Inst* 99: 1875-1880, 2007.
22. Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, *et al*: Increased cancer risk of heterozygotes with *NBS1* germline mutations in Poland. *Int J Cancer* 111: 67-71, 2004.
23. Seemanová E, Sperling K, Neitzel H, Varon R, Hadac J, Butova O, Schröck E, Seeman P and Digweed M: Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability. *J Med Genet* 43: 218-224, 2006.
24. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K and Seeger K: Mutations in the Nijmegen Breakage Syndrome gene (*NBS1*) in childhood acute lymphoblastic leukemia (ALL). *Cancer Res* 61: 3570-3572, 2001.
25. Hebring SJ, Fredriksson H, White KA, Maier C, Ewing C, McDonnell SK, Jacobsen SJ, Cerhan J, Schaid DJ, Ikonen T, *et al*: Role of the Nijmegen breakage syndrome gene in familial and sporadic prostate cancer. *Cancer Epidemiol Biomarkers Prev* 15: 935-938, 2006.